NO20005081L - A polypeptide comprising the amino acid of an N-terminal choline binding protein A truncate, vaccine derived therefrom and uses thereof - Google Patents

A polypeptide comprising the amino acid of an N-terminal choline binding protein A truncate, vaccine derived therefrom and uses thereof

Info

Publication number
NO20005081L
NO20005081L NO20005081A NO20005081A NO20005081L NO 20005081 L NO20005081 L NO 20005081L NO 20005081 A NO20005081 A NO 20005081A NO 20005081 A NO20005081 A NO 20005081A NO 20005081 L NO20005081 L NO 20005081L
Authority
NO
Norway
Prior art keywords
amino acid
polypeptide
binding protein
choline binding
acid sequence
Prior art date
Application number
NO20005081A
Other languages
Norwegian (no)
Other versions
NO20005081D0 (en
Inventor
Elaine I Tuomanen
H Robert Masure
Theresa M Wizemann
Leslie Sydnor Johnson
Scott Koenig
Original Assignee
St Jude Childrens Res Hospital
Medimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/056,019 external-priority patent/US6858706B2/en
Application filed by St Jude Childrens Res Hospital, Medimmune Inc filed Critical St Jude Childrens Res Hospital
Publication of NO20005081D0 publication Critical patent/NO20005081D0/en
Publication of NO20005081L publication Critical patent/NO20005081L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Oppfinnelsen frembringer et isolert polypeptid som omfatter en aminosyresekvens av et N-terminalt kolinbindende protein A trunkat hvori aminosyresekvensen er fremlagt i en. av SEQ ID NOS: 1, 3-7, eller 9-11, inklusive fragmenter, mutanter, varianter, analoger eller derivater derav. Videre frembringer denne oppfinnelse isolerte polypeptider som omfatter en aminosyresekvens av et N-terminalt kolinbindende protein A trunkat, hvori aminosyren er fremlagt i SEQ ID NO 24, hvori polypeptidet beholder sin opprinnelige tertiære struktur og fremgangsmåter til fremstilling. Denne oppfinnelse frembringer et". isolert polypeptid som omfatter en aminosyresekvens av et N-terminalt kolinbindende protein A trunkat, hvori polypeptidet har lektinaktivitet og ikke bindes til kolinet. Oppfinnelsen frembringer et isolert immunogent polypeptid som omfatter en aminosyresekvens for et N-terminalt kolinbindende protein A trunkat. Oppfinnelsen frembringer en isolert nukleinsyre som koder for et polypeptid som omfatter en aminosyresekvens for N-terminalt kolinbindende protein A trunkat. Endelig frembringer denne oppfinnelse farmasøytiske preparater, vaksiner og diagnostiske og terapeutiske fremgangsmåter til anvendelse.The invention provides an isolated polypeptide comprising an amino acid sequence of an N-terminal choline binding protein A truncate wherein the amino acid sequence is presented in a. of SEQ ID NOS: 1, 3-7, or 9-11, including fragments, mutants, variants, analogs or derivatives thereof. Furthermore, this invention provides isolated polypeptides comprising an amino acid sequence of an N-terminal choline binding protein A truncate, wherein the amino acid is set forth in SEQ ID NO 24, wherein the polypeptide retains its original tertiary structure and methods of preparation. This invention provides an "isolated polypeptide comprising an amino acid sequence of an N-terminal choline binding protein A trunkate, wherein the polypeptide has lectin activity and does not bind to the choline. The invention provides an isolated immunogenic polypeptide comprising an amino acid sequence of an N-terminal choline binding protein A The invention provides an isolated nucleic acid encoding a polypeptide comprising an amino acid sequence of N-terminal choline binding protein A. truncate Finally, this invention provides pharmaceutical compositions, vaccines and diagnostic and therapeutic methods for use.

NO20005081A 1998-04-07 2000-10-09 A polypeptide comprising the amino acid of an N-terminal choline binding protein A truncate, vaccine derived therefrom and uses thereof NO20005081L (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8087898P 1998-04-07 1998-04-07
US09/056,019 US6858706B2 (en) 1998-04-07 1998-04-07 Polypeptide comprising the amino acid of an N-terminal choline binding protein a truncate, vaccine derived therefrom and uses thereof
PCT/US1999/007669 WO1999051188A2 (en) 1998-04-07 1999-04-07 A polypeptide comprising the amino acid of an n-terminal choline binding protein a truncate, vaccine derived therefrom and uses thereof

Publications (2)

Publication Number Publication Date
NO20005081D0 NO20005081D0 (en) 2000-10-09
NO20005081L true NO20005081L (en) 2000-12-06

Family

ID=26734874

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20005081A NO20005081L (en) 1998-04-07 2000-10-09 A polypeptide comprising the amino acid of an N-terminal choline binding protein A truncate, vaccine derived therefrom and uses thereof

Country Status (14)

Country Link
JP (1) JP4739521B2 (en)
KR (1) KR100638503B1 (en)
CN (1) CN1191851C (en)
AU (2) AU3479699A (en)
BR (1) BR9909910A (en)
CA (1) CA2326388C (en)
HU (1) HUP0102306A3 (en)
IL (1) IL138939A0 (en)
MX (1) MXPA00009899A (en)
NO (1) NO20005081L (en)
NZ (1) NZ507983A (en)
PL (1) PL193132B1 (en)
TR (1) TR200003498T2 (en)
WO (1) WO1999051188A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0022742D0 (en) * 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
TWI457133B (en) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa Novel composition
KR101515078B1 (en) 2005-12-22 2015-04-24 글락소스미스클라인 바이오로지칼즈 에스.에이. Vaccines
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
CA2690708A1 (en) 2007-06-26 2008-12-31 Glaxosmithkline Biologicals S.A. Vaccine
ES2553113T3 (en) 2008-04-16 2015-12-04 Glaxosmithkline Biologicals S.A. Vaccine
GB201003924D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
CN103533953A (en) 2011-05-17 2014-01-22 葛兰素史密丝克莱恩生物有限公司 Vaccine against Streptococcus pneumoniae
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
GB201711635D0 (en) 2017-07-19 2017-08-30 Glaxosmithkline Biologicals Sa Immunogenic composition

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6592876B1 (en) * 1993-04-20 2003-07-15 Uab Research Foundation Pneumococcal genes, portions thereof, expression products therefrom, and uses of such genes, portions and products
ES2262177T3 (en) * 1996-05-01 2006-11-16 The Rockefeller University PROTEINS OF UNION TO HILL FOR VACCINES AGAINST NEUMOCOCOS.
JP4469026B2 (en) * 1996-10-31 2010-05-26 ヒューマン ジノーム サイエンシーズ，インコーポレイテッド Streptococcus pneumoniae antigens and vaccines
JP2002503087A (en) * 1996-11-12 2002-01-29 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ Streptococcus pneumoniae C3 binding protein
DE69942176D1 (en) * 1998-04-07 2010-05-06 Medimmune Llc CHOLINE-BINDING PROTEIN DERIVATIVES FROM PNEUMOCOKES AS A VACCINE
US6858706B2 (en) * 1998-04-07 2005-02-22 St. Jude Children's Research Hospital Polypeptide comprising the amino acid of an N-terminal choline binding protein a truncate, vaccine derived therefrom and uses thereof

Also Published As

Publication number Publication date
BR9909910A (en) 2002-01-15
NO20005081D0 (en) 2000-10-09
CA2326388C (en) 2014-02-04
CA2326388A1 (en) 1999-10-14
WO1999051188A3 (en) 2001-04-19
JP2002516662A (en) 2002-06-11
AU3479699A (en) 1999-10-25
AU764811B2 (en) 2003-08-28
NZ507983A (en) 2004-03-26
TR200003498T2 (en) 2001-10-22
MXPA00009899A (en) 2002-05-08
WO1999051188A2 (en) 1999-10-14
PL347946A1 (en) 2002-04-22
KR100638503B1 (en) 2006-10-26
HUP0102306A1 (en) 2001-09-28
WO1999051188A9 (en) 2000-10-12
KR20010052244A (en) 2001-06-25
AU3479799A (en) 1999-10-25
CN1191851C (en) 2005-03-09
HUP0102306A3 (en) 2008-04-28
JP4739521B2 (en) 2011-08-03
IL138939A0 (en) 2001-11-25
PL193132B1 (en) 2007-01-31
CN1342088A (en) 2002-03-27

Similar Documents

Publication Publication Date Title
KR102482994B1 (en) Vaccine composition for preventing or treating infection of SARS-CoV-2
AU2019210579B2 (en) RSV F protein mutants
EP4163291A1 (en) Polypeptide vaccine coupled with tlr7 agonist for novel coronavirus and use thereof
Solioz et al. The protective capacities of histone H1 against experimental murine cutaneous leishmaniasis
PT754231E (en) PEPTIDE FRAGMENT OF SINCIAL RESPIRATORY VIRUS PROTEIN G, IMMUNOGENIC AGENT, PHARMACEUTICAL COMPOSITION CONTAINING AND PREPARATION PROCESS
ES2398492T3 (en) Fusion proteins comprising the tumor rejection antigens NY-ESO-1 and LAGE-1
US20230338510A1 (en) Novel coronavirus tandem epitope polypeptide vaccine and use thereof
Davis et al. Basic fibroblast growth factor induces 3T3 fibroblasts to synthesize and secrete a cyclophilin-like protein and β2-microglobulin
NO20005081L (en) A polypeptide comprising the amino acid of an N-terminal choline binding protein A truncate, vaccine derived therefrom and uses thereof
JP2019013229A (en) CyaA-based chimeric proteins containing heterologous polypeptides and their use in inducing immune responses
US20100029912A1 (en) Fusion Protein
EP1849870A1 (en) Immunoreactive and immunotherapeutic molecules which interact in subjects with insulin-dependent diabetes mellitus (IDDM)
PT1219301E (en) Vaccines containing hybrid polypeptides consisting of at least two different allergenic proteins
WO2000029434A3 (en) PNEUMOCOCCAL CHOLINE BINDING PROTEINS, CbpG AND CbpD, DIAGNOSTIC AND THERAPEUTIC USES THEREOF
JP2025503079A5 (en)
KR20220056817A (en) Vaccine composition for preventing or treating infection of SARS-CoV-2
US20230192777A1 (en) Epitopic vaccine for african swine fever virus
US11413345B2 (en) Synthetic hemagglutinin as universal vaccine against infection by type B influenza viruses (IBV)
KR102369146B1 (en) Formulation of Corona virus vaccine
CN114621329A (en) T cell epitope peptide compound
US20250177514A1 (en) Coronavirus antigen variants
US20250121053A1 (en) Vaccine compositions and their use
CN118678968A (en) Vaccine composition and use thereof
CN119978138A (en) Vaccine composition containing conservative recombinant protein fragments of coronavirus and its application
KR20160040553A (en) Composition for treating and preventing multiple sclerosis

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application
FC2A Withdrawal, rejection or dismissal of laid open patent application